July 2025

Marketing Material

Bionics P USD

With a growing imbalance between healthcare demand and workforce, Bionics - the cutting-edge of Medtech - expands its addressable market much faster than global GDP. Innovation makes for advanced care, longer lifespan, better wellness, and lower total costs. Pure-players revolutionizing healthcare through tech have an opportunity to grow aggressively their revenues and, more importantly, their earnings over the next several years.

The strategy’s investment objective is to achieve long-term capital appreciation by allocating investments to such companies depending on their growth rate and quality.

Fund Information
Fund Atonra Bionics
Umbrella AtonRâ SICAV
Domicile Luxembourg
Category UCITS
Asset Class Equity
Fund Inception 2024-10-01
Fund Currency USD
Total assets USD 22Mn
# Holdings 29
Investment Manager AtonRâ Partners SA
Management Company Fundsight (ex-Lemanik)
Custody, Administration and Transfer Agent Société Générale Luxembourg (SGSS)
Share Class Information
Share Class P USD
ISIN LU2888501942
Inception 2024-11-26
Currency USD
NAV (31/07/25) USD 94.95
NAV Frequency Daily
Reference Index MSCI ACWI Net TR (USD)
Sharpe Ratio -0.42
Correlation 0.80
Beta 1.27
Minimum Subscription USD 100
Cut-off Time T-1 13:00 CET
Management Fees 1.50%
Performance Fees 15.00%
ALL TIME HIGH ALL TIME LOW
PRICE: 105.6 PRICE: 80.7
DATE: 2025-02-19 DATE: 2025-04-08

Bionics P USD

With a growing imbalance between healthcare demand and workforce, Bionics - the cutting-edge of Medtech - expands its addressable market much faster than global GDP. Innovation makes for advanced care, longer lifespan, better wellness, and lower total costs. Pure-players revolutionizing healthcare through tech have an opportunity to grow aggressively their revenues and, more importantly, their earnings over the next several years.

The strategy’s investment objective is to achieve long-term capital appreciation by allocating investments to such companies depending on their growth rate and quality.

Monthly Returns $

(Net of fees)

* Estimated
* Actual

JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC ANNUAL
2025 6.8% -2.8% -10.3% 4.6% 7.4% 1.6% -5.9% -0.0%
2024 1.3% -6.2% -5.0%
Industry Exposure

Top Holdings
  • INSULET (5.57%)
  • PRO MEDICUS LIMITED (5.24%)
  • NATERA INC (4.85%)
Top 3 Contributors
  • HIMS & HERS HEALTH
  • PRO MEDICUS LIMITED
  • BONESUPPORT HOLDING AB
Worst 3 Contributors
  • NATERA INC
  • NOVOCURE
  • GLAUKOS
Geographical
Breakdown
Currency
Exposure
Asset
Allocation
Equity Market Cap
Distribution
Equity
Liquidity*

*On average 3 Months daily trading volume

Risk
Scale

4


The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back

Industry Exposure

The AtonRâ Fund Share Classes And Loads
isin price reuters currency dividend bloomberg mgmt. fees perf. fees launch date share class min subscription
LU2888501942 94.95 LP68839494 USD CAPITALISATION BIONIPU 1.50% 15.00% 2024-11-26 P USD $ 100
LU2888501868 96.73 LP68831804 USD CAPITALISATION BIONIZU 0.00% 0.00% 2024-09-30 Institutional Z $ 100
LU2888501512 95.90 LP68831803 USD CAPITALISATION BIONIFU 1.00% 0.00% 2024-10-01 Founder Class $ 100